News
Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc.
The American Cancer Society expects 600,920 Americans to die from cancer this year, but Ziopharm Oncology Inc. (NASDAQ: ZIOP) and Celldex Therapeutics, Inc. (NASDAQ: CLDX) aim to lower that....
Will Johnson & Johnson Do a Stock Split in 2018?
Healthcare has been an exciting industry lately, and Johnson & Johnson (NYSE: JNJ) casts a wide net over the sector. The company not only sells well-known consumer brands like Tylenol and....
Are Viruses a Problem for CAR-T Drugmakers?
Chimeric antigen receptor T-cell therapy (CAR-T) could change how doctors treat cancer patients; however, creating these drugs is complicated and a flurry of research and commercialization....
Better Buy: GlaxoSmithKline plc vs. Pfizer
Big drug companies can add an element of stability to investor portfolios. People get sick and need treatment whether the economy is booming or tanking. And big pharma tends to pay hefty....
Healthcare Investing Risks and How to Mitigate Them
Healthcare is constantly coming under the fire of political and media attention, and biotech companies are going boom or bust on FDA approvals that are out of their control. But healthcare is also....
What You Need to Know About Systematic Risk
We're a stock-picking company at The Motley Fool, and we tend to sing the praises of investing in individual companies for the long term -- but that's not to say that stock-picking is without its....
Here's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017
After a horrible 2016 following the loss of its lead drug candidate, Alnylam Pharmaceuticals (NASDAQ: ALNY) has had a pretty stellar year, up 238% so far.Much of that increase has come in the last....
Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017
For Celldex Therapeutics (NASDAQ: CLDX), 2016 was a horrible year. The biotech stock dropped 77% after experimental vaccine Rintega flopped in a late-stage clinical study. Celldex entered 2017....
3 Top Big Pharma Stocks to Buy Now
Big pharma stocks have been longtime favorites among investors for several reasons. The fact that they're big means that that they generate huge cash flow, which typically translates to attractive....
3 Dividend Stocks With Better Yields Than McDonald's
If you want fast food, McDonald's Corporation (NYSE: MCD) might be a good option. But despite the stock's status as a Dividend Aristocrat, there are better alternatives than McDonald's if you're....
3 Growth Stocks for the Long Term
What investor doesn't like growth? If a stock generates enough growth, dividends and valuation become relatively insignificant. Growth is king.We asked three Motley Fool investors which growth....
Is First Data Corp. a Buy?
First Data Corp. (NYSE: FDC) is a payment-processing company that offers retailers card and mobile payment acceptance capabilities for online and point-of-sale (POS) transactions. First Data is....
Why Aratana Therapeutics Inc. Is Tanking Today
In response to announcing a secondary common stock offering, shares of Aratana Therapeutics (NASDAQ: PETX), a commercial stage biotech focused on pet health, fell 14% as of 11:35 a.m. EST on....
Evotec: Schnäppchen oder fallendes Messer?
Evotec ist in diesen Tagen wieder in aller Munde. Der Aktienkurs kommt nicht auf die Beine und nach dem Ausverkauf der letzten Wochen um zeitweise bis zu 46 Prozent auf 12 EUR, wittern viele....
Why Omeros Corporation Is the Best Buy in Biotech Right Now
Omeros Corporation (NASDAQ: OMER) stock soared after the company reported surprisingly good results recently, but there's a lot more fuel in the tank to propel it even higher. This small-cap....
This Small-Cap Biotech Stock Is Onto Something Big
I recently had the pleasure of chatting with Flexion Therapeutics (NASDAQ: FLXN) CEO Mike Clayman about the company's plans for Zilretta, a newly approved medicine treating osteoarthritis of the....
Biogen Inc. Buys Its Way Out of Competition
Biogen (NASDAQ: BIIB) is following the old saying, "If you can't beat 'em, join 'em" for its multibillion drug Tecfidera or, more accurately, "If you might not be able to beat 'em later, license....
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
These big pharma stocks have something for everyone. Income investors love the dividends Eli Lilly and Co. (NYSE: LLY) and Merck & Co., Inc. (NYSE: MRK) pay each quarter, while dreams of....
3 Top Diabetes Stocks to Buy Now
Diabetes is huge problem for Americans. Between 1990 and 2010, the number of U.S. residents with diabetes tripled, and the number of new cases annually doubled. Both prevalence and costs....
The Federal Government Just Broke Its Medical-Marijuana Promise
Few if any industries are growing at a quicker and more consistent pace in the U.S. than marijuana. A report released earlier this year by Marijuana Business Daily entitled "Marijuana Business....
5 Cancer Types With the Poorest Long-Term Outlook
There's arguably no scarier diagnosis a patient can receive from their doctor than cancer. But the grim reality, based on data from the National Cancer Institute's Surveillance, Epidemiology, and....
How to Diversify Your Healthcare Investments
On this week's episode of Industry Focus: Healthcare, analysts Kristine Harjes and Todd Campbell get back to basics and explain what you need to know about diversifying your portfolio, especially....
Why Collegium Pharmaceutical Shares Are Tumbling 12.9% Today
After FDA commissioner Scott Gottlieb issued a statement suggesting an easier path to winning approval for generic opioids that are abuse deterrent, shares in Collegium Pharmaceutical's (NASDAQ:....
Why Marijuana Stock GW Pharmaceuticals Skyrocketed 11% Today
After the company released updated clinical trial data showing efficacy of its marijuana drug as a monotherapy and improvement from baseline over long-term use, shares of GW....
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
At a recent healthcare conference, Gilead Sciences (NASDAQ: GILD) CEO John Milligan laid out his top three priorities for 2018. Here's what he said (this and all other quotes courtesy of S&P....